Highly potent autophagy-inducing peptides now exclusively available from Novus Biologicals, a Bio-Techne brand

MINNEAPOLIS, Minnesota [July 18, 2016] – Bio-Techne Corporation, a global life sciences company providing innovative biotechnology research tools and instruments for the academic, biotech, pharma and diagnostic communities announced today the launch of several new products for the study of autophagy.  The Tat-L11, Tat-D11, and Tat-L11S Control Peptides are available exclusively under the Novus Biologicals brand. Autophagy is a biological process that allows the orderly degradation and recycling of cellular components and is involved in numerous pathological/physiological processes, including cancer, metabolic and neurodegenerative disorders, and cardiovascular/pulmonary diseases.

"We are very excited to release these products to the scientific research community," says Dr. Cyrus Munshi, Manager of Eukaryotic Systems & Recombinant Antibody Development at Bio-Techne. "These peptides offer a unique combination of potency and specificity that will greatly enhance experimental procedures that require autophagy induction. Current methods such as starvation and inhibition of MTORC1 have multiple downstream effects outside of autophagy pathways that can make interpretation of results quite challenging. The use of engineered peptides to induce autophagy has been well accepted as the best means of directly studying autophagy pathways."

"The Tat-L11 and Tat-D11 peptides now available through Novus Biologicals have an additional advantage of very high induction rates when compared to other commercially available peptides such as Tat-Beclin 1.  These products offer a solution to several challenges faced by researchers studying autophagy and we look forward to seeing them used in many new experiments," says Dr. Munshi. A comparison of the new peptides to the original Tat-Beclin 1 peptides is available in the new whitepaper published through Novus Biologicals, Inducing Autophagy: Tat-D11, a highly potent and specific autophagy-inducing peptide.

The addition of the Tat-L11 and Tat-D11 peptides to the Novus Biologicals brand fills out their extensive and highly validated portfolio of products for autophagy research. Novus autophagy-related antibodies including antibodies against LC3, LC3B, ATG5, ATG9A and Beclin 1 have been cited in thousands of articles in peer-reviewed journals.

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $452 million in net sales in fiscal 2015 and has approximately 1,500 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.

About Novus Biologicals
Novus Biologicals®, a Bio-Techne brand, accelerates scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies and proteins to the bioscience community. All of its products are 100% guaranteed to conform to the application claims listed on the datasheet. Novus Biologicals is committed to innovation and has formed and will continue to form ongoing partnerships with leading researchers. For more information visit www.novusbio.com.

Contact: Karen Padgett, VP of Antibody Business Unit and Digital Marketing
Phone: 303 730 1950
Fax: 303 730 1966
Emailkaren.padgett@bio-techne.com

Release Date: 
Monday, July 18, 2016 - 08:30